August 3, 2023 02:28 PM EDT

FDA’s decentralized trial guidance: PhRMA, Mayo Clinic and others seek tweaks

Lia DeGroot

After the FDA this past spring laid out its approach to decentralized clinical trials, stakeholders are largely welcoming the guidance, but are asking the agency …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA’s decentralized trial guidance: PhRMA, Mayo Clinic and others seek tweaks

Lia DeGroot

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

FDA’s de­cen­tral­ized tri­al guid­ance: PhRMA, Mayo Clin­ic and oth­ers seek tweaks

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA’s decentralized trial guidance: PhRMA, Mayo Clinic and others seek tweaks